Whistleblower Doctor: U.S. Fumbled AIDS Data
Federal officials involved in a U.S.-funded research project in Uganda were more interested in promoting an AIDS drug than patient safety, says a government whistleblower. The research was aimed at finding ways to protect babies in Africa from HIV infection. In prepared remarks for a hearing Tuesday, Dr. Jonathan Fishbein charged that the study in Uganda was "so poorly conducted that its data must be rendered invalid as a matter of law, policy, and human health." The hearing before a National Academy of Sciences panel marked Fishbein's first public testimony since a series of articles by The Associated Press detailing problems with the project. Fishbein, who is fighting a decision by the National Institutes of Health to fire him, is one of several employees at the government's premier health research agency to question the Uganda study. It involved giving the AIDS drug, nevirapine, to pregnant women to prevent HIV transmission to their babies. NIH has acknowledged that the Uganda research failed to meet required U.S. standards. But it maintains hundreds of thousands of African babies have been saved by using single doses of the drug to block the AIDS virus. Nevirapine is an antiretroviral drug used since the 1990s to treat adult AIDS patients and is known to have potentially lethal side effects like liver damage when taken in multiple doses over time. New concerns have surfaced more recently that nevirapine also may cause long-term resistance in patients to further AIDS treatments. It is marketed in the United States as Viramune. Fishbein, an expert hired by the National Institutes of Health to improve agency research practices, said top officials at NIH became "so heavily invested in the (Uganda) trial's outcome" that they could not be objective. [more]